We spoke to Dr. Mousa Shamonki, a fertility specialist, for more information. Dr. Shamonki explained that “Ferring has pulled Bravelle off the shelf due to concerns about a shorter-than-expected half-life of the medicine. Because a shorter half-life would potentially result in a lower drug potency, Ferring has recalled Bravelle nationwide in order to troubleshoot the problem, solve it, then produce Bravelle with high potency expected by fertility doctors and their patients.”
The GoodRx team is investigating to bring you further updates, but at this time it appears that Bravelle may be soon be unavailable. Ferring has Bravelle listed as backordered, and will not be shipping any more in the near future, according to a pharmacist posting on social networking and news site Reddit.
How does this affect you? Your pharmacy cannot sell a drug that has been recalled. This may be especially complicated if you are in the middle of a fertility cycle, and you may want to reach out to your doctor’s office to find out what your options are.
What is Bravelle used for?
Bravelle is a type of follicle-stimulating hormone (FSH) used as a first-line treatment to help with ovulation and fertility, often used for in vitro fertilization (IVF). Dr. Sharon Orrange explains, “Controlled ovarian stimulation in women undergoing treatment for in vitro fertilization (IVF) is usually provided with combinations of FSH (follicle stimulating hormone) and LH (luteinizing hormone). The decision as to the most effective preparations is a common debatable issue, and the choice of gonadotropin (LH and FSH) should depend on availability, convenience, and cost.”
Does it make a difference which FSH treatment you receive?
According to Dr. Orrange, “differences between the urinary gonadatrophins [like Bravelle] and recombinant FSH [like Follistim or Gonal] have been studied and not been found to be clinically significant. With news of a recall of Bravelle, know there are several equivalent options for treatment and success.”
We will continue to update this article as we find out more.